Antibody Drug SHR-4849 Shows Early Promise Against Small-Cell Lung Cancer In First Human Trial
A new antibody-drug, SHR-4849, has shown encouraging results in treating relapsed small-cell lung cancer (SCLC) in its first-in-human trial.
A new antibody-drug, SHR-4849, has shown encouraging results in treating relapsed small-cell lung cancer (SCLC) in its first-in-human trial.
